Literature DB >> 26022944

Comparisons of the clinicopathological features and survival outcomes between lung cancer patients with adenocarcinoma and squamous cell carcinoma.

Takayuki Fukui1, Tetsuo Taniguchi, Koji Kawaguchi, Koichi Fukumoto, Shota Nakamura, Yukinori Sakao, Kohei Yokoi.   

Abstract

OBJECTIVE: Patients with lung cancer should be treated according to histological subtype because of the disparities in tumor aggressiveness and treatment responses. It is important to re-evaluate the clinicopathological features of the two major subtypes of lung cancer, adenocarcinoma (AD) and squamous cell carcinoma (SQ).
METHODS: We retrospectively analyzed data on the clinicopathological features and outcomes of 2059 patients with pulmonary AD and pulmonary SQ who had undergone complete resection at Nagoya University Hospital and Aichi Cancer Center between 1995 and 2012.
RESULTS: The cohort consisted of 1587 patients with AD (77 %) and 472 with SQ (23 %). Female gender, no history of smoking, and small tumor size were distinct characteristics of AD patients, and a higher age was a characteristic of SQ patients (p < 0.0001). A significant difference was observed in overall survival, with 5-year survival rates of 78 % in AD patients and 63 % in SQ patients. Patients with stage IA and IB SQ had significantly worse outcomes than patients with AD at the same stage (p < 0.0001). Because no survival difference was observed between SQ patients with stage IA, IB, and IIA tumors (p = 0.75), these patients were considered to have proposed stage IIA disease. Then, comparable survival curves were obtained between stages II and IIIA SQ and AD.
CONCLUSIONS: Patients with stage I SQ had significantly worse outcomes than patients with stage I AD. A newly defined stage grouping for SQ patients provided outcomes comparable to those of AD patients.

Entities:  

Mesh:

Year:  2015        PMID: 26022944     DOI: 10.1007/s11748-015-0564-5

Source DB:  PubMed          Journal:  Gen Thorac Cardiovasc Surg        ISSN: 1863-6705


  19 in total

1.  Clinical biology of small cell carcinoma: relationship to surgical therapy.

Authors:  C F Mountain
Journal:  Semin Oncol       Date:  1978-09       Impact factor: 4.929

2.  Peripheral lung adenocarcinoma: correlation of thin-section CT findings with histologic prognostic factors and survival.

Authors:  T Aoki; Y Tomoda; H Watanabe; H Nakata; T Kasai; H Hashimoto; M Kodate; T Osaki; K Yasumoto
Journal:  Radiology       Date:  2001-09       Impact factor: 11.105

3.  Cancer of the esophagus and esophagogastric junction: data-driven staging for the seventh edition of the American Joint Committee on Cancer/International Union Against Cancer Cancer Staging Manuals.

Authors:  Thomas W Rice; Valerie W Rusch; Hemant Ishwaran; Eugene H Blackstone
Journal:  Cancer       Date:  2010-08-15       Impact factor: 6.860

4.  The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours.

Authors:  Peter Goldstraw; John Crowley; Kari Chansky; Dorothy J Giroux; Patti A Groome; Ramon Rami-Porta; Pieter E Postmus; Valerie Rusch; Leslie Sobin
Journal:  J Thorac Oncol       Date:  2007-08       Impact factor: 15.609

5.  Proportion of ground-glass opacity on high-resolution computed tomography in clinical T1 N0 M0 adenocarcinoma of the lung: A predictor of lymph node metastasis.

Authors:  Haruhisa Matsuguma; Kohei Yokoi; Masaki Anraku; Tetsuro Kondo; Yukari Kamiyama; Kiyoshi Mori; Keigo Tominaga; Yukio Tsuura; Satoshi Honjo
Journal:  J Thorac Cardiovasc Surg       Date:  2002-08       Impact factor: 5.209

6.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.

Authors:  Nasser Hanna; Frances A Shepherd; Frank V Fossella; Jose R Pereira; Filippo De Marinis; Joachim von Pawel; Ulrich Gatzemeier; Thomas Chang Yao Tsao; Miklos Pless; Thomas Muller; Hong-Liang Lim; Christopher Desch; Klara Szondy; Radj Gervais; Christian Manegold; Sofia Paul; Paolo Paoletti; Lawrence Einhorn; Paul A Bunn
Journal:  J Clin Oncol       Date:  2004-05-01       Impact factor: 44.544

7.  EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Authors:  J Guillermo Paez; Pasi A Jänne; Jeffrey C Lee; Sean Tracy; Heidi Greulich; Stacey Gabriel; Paula Herman; Frederic J Kaye; Neal Lindeman; Titus J Boggon; Katsuhiko Naoki; Hidefumi Sasaki; Yoshitaka Fujii; Michael J Eck; William R Sellers; Bruce E Johnson; Matthew Meyerson
Journal:  Science       Date:  2004-04-29       Impact factor: 47.728

8.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Authors:  Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia L Harris; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeff Settleman; Daniel A Haber
Journal:  N Engl J Med       Date:  2004-04-29       Impact factor: 91.245

9.  Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

Authors:  Giorgio Vittorio Scagliotti; Purvish Parikh; Joachim von Pawel; Bonne Biesma; Johan Vansteenkiste; Christian Manegold; Piotr Serwatowski; Ulrich Gatzemeier; Raghunadharao Digumarti; Mauro Zukin; Jin S Lee; Anders Mellemgaard; Keunchil Park; Shehkar Patil; Janusz Rolski; Tuncay Goksel; Filippo de Marinis; Lorinda Simms; Katherine P Sugarman; David Gandara
Journal:  J Clin Oncol       Date:  2008-05-27       Impact factor: 44.544

Review 10.  Controversy about small peripheral lung adenocarcinomas: how should we manage them?

Authors:  Takayuki Fukui; Noriaki Sakakura; Shoichi Mori; Shunzo Hatooka; Masayuki Shinoda; Yasushi Yatabe; Tetsuya Mitsudomi
Journal:  J Thorac Oncol       Date:  2007-06       Impact factor: 15.609

View more
  18 in total

1.  Histological type predicts mediastinal metastasis and surgical outcome in resected cN1 non-small cell lung cancer.

Authors:  Tetsuya Mizuno; Takaaki Arimura; Hiroaki Kuroda; Noriaki Sakakura; Yasushi Yatabe; Yukinori Sakao
Journal:  Gen Thorac Cardiovasc Surg       Date:  2017-06-28

2.  Texture Analysis on [18F]FDG PET/CT in Non-Small-Cell Lung Cancer: Correlations Between PET Features, CT Features, and Histological Types.

Authors:  Francesco Bianconi; Isabella Palumbo; Mario Luca Fravolini; Rita Chiari; Matteo Minestrini; Luca Brunese; Barbara Palumbo
Journal:  Mol Imaging Biol       Date:  2019-12       Impact factor: 3.488

3.  Platinum-Based Adjuvant Chemotherapy for Stage II and Stage III Squamous Cell Carcinoma of the Lung.

Authors:  Tetsuya Isaka; Haruhiko Nakayama; Tomoyuki Yokose; Hiroyuki Ito; Kayoko Katayama; Kouzo Yamada; Munetaka Masuda
Journal:  Ann Thorac Cardiovasc Surg       Date:  2016-12-27       Impact factor: 1.520

4.  Choice of the surgical approach for patients with stage I lung squamous cell carcinoma ≤3 cm.

Authors:  Chunji Chen; Yiyang Wang; Xufeng Pan; Shijie Fu; Yubo Shi; Jun Yang; Rui Wang
Journal:  J Thorac Dis       Date:  2018-12       Impact factor: 2.895

5.  Radiomic signature as a diagnostic factor for histologic subtype classification of non-small cell lung cancer.

Authors:  Xinzhong Zhu; Di Dong; Zhendong Chen; Mengjie Fang; Liwen Zhang; Jiangdian Song; Dongdong Yu; Yali Zang; Zhenyu Liu; Jingyun Shi; Jie Tian
Journal:  Eur Radiol       Date:  2018-02-15       Impact factor: 5.315

6.  Radiomics for Classifying Histological Subtypes of Lung Cancer Based on Multiphasic Contrast-Enhanced Computed Tomography.

Authors:  Linning E; Lin Lu; Li Li; Hao Yang; Lawrence H Schwartz; Binsheng Zhao
Journal:  J Comput Assist Tomogr       Date:  2019 Mar/Apr       Impact factor: 1.826

7.  Prognostic impact of controlling nutritional status score in resected lung squamous cell carcinoma.

Authors:  Gouji Toyokawa; Yuka Kozuma; Taichi Matsubara; Naoki Haratake; Shinkichi Takamori; Takaki Akamine; Kazuki Takada; Masakazu Katsura; Mototsugu Shimokawa; Fumihiro Shoji; Tatsuro Okamoto; Yoshihiko Maehara
Journal:  J Thorac Dis       Date:  2017-09       Impact factor: 2.895

8.  An Artificial Intelligence Model for Predicting 1-Year Survival of Bone Metastases in Non-Small-Cell Lung Cancer Patients Based on XGBoost Algorithm.

Authors:  Zhangheng Huang; Chuan Hu; Changxing Chi; Zhe Jiang; Yuexin Tong; Chengliang Zhao
Journal:  Biomed Res Int       Date:  2020-06-27       Impact factor: 3.411

9.  POLE2 Serves as a Prognostic Biomarker and Is Associated with Immune Infiltration in Squamous Cell Lung Cancer.

Authors:  Zhen Wu; Yue-Ming Wang; Yu Dai; Liang-An Chen
Journal:  Med Sci Monit       Date:  2020-04-18

10.  Differences in the early stage gene expression profiles of lung adenocarcinoma and lung squamous cell carcinoma.

Authors:  Nitin Venugopal; Justin Yeh; Sai Karthik Kodeboyina; Tae Jin Lee; Shruti Sharma; Nikhil Patel; Ashok Sharma
Journal:  Oncol Lett       Date:  2019-10-21       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.